首页> 外文期刊>Cost Effectiveness Resource Allocation >The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible
【24h】

The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible

机译:使用高级胶质瘤患者使用脑激光间质疗法(LITT)系统的价值,最大安全切除可能不可行

获取原文
获取外文期刊封面目录资料

摘要

The objective of this analysis was to determine the value (incremental cost/increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open resection (i.e. craniotomy) methods or biopsy (collectively termed CURRENT TREATMENTS) in patients where maximal safe resection may not be feasible. As has been demonstrated in the literature, extent of resection/ablation with minimal complications are independently related to overall survival. A cost effectiveness analysis from a societal perspective was employed using TreeAge Pro 2014 software. Direct costs (using national average Medicare reimbursement amounts), outcomes (overall survival), and value [defined as increment cost/incremental survival-evaluated as cost/life year gained (LYG)] were evaluated. Sensitivity analysis was also performed to determine which variables had the largest effect on incremental costs and outcomes. In the base case, the overall survival was improved with brain LITT versus CURRENT TREATMENTS by 3.07?months at an additional cost of $7508 (or $29,340/LYG). This amount was significantly less than the current international threshold value for $32,575/LYG and considerably less than the US threshold value of $50,000/LYG. This incremental cost may also qualify under NICE criteria for end of life therapies. In sensitivity analysis: As percent local recurrence GBM increased; cost of DRG25/26 increased; percent GTR increased; and gliadel use increased-the value of brain LITT improved. Additionally, in those patients where a biopsy is the only option, brain LITT extended life by 7?months. Brain LITT should be considered a viable option for treatment of high grade gliomas as it improves survival at a cost which appears to be of good value to society. This incremental cost is less than the international and US thresholds for good value.
机译:该分析的目的是确定脑LITT系统与采用NCCN指南推荐的当前手术选项的价值(增量成本/增量效益),特别是开放的切除(即Craniotmy)方法或患者活检(集体称为当前治疗)最大安全切除可能不可行。正如在文献中所证明的那样,切除/消融的程度与最小并发症的融合与总体存活无关。使用Treeage Pro 2014软件采用了社会角度的成本效益分析。直接费用(使用国家平均医疗保险报销金额),结果(总体存活)和值[定义为增量成本/增量存活,评价为成本/终天(LYG)]进行了评估。还进行了敏感性分析,以确定哪些变量对增量成本和结果产生最大影响。在基本情况下,将脑LITT与当前治疗的总体存活率提高了3.07次,以7508美元的额外费用(或29,340美元/ Lyg)。此金额明显低于当前的国际阈值,以32,575美元/ LYG,比美国阈值大于50,000美元/ LYG。这种增量成本也可能在终身疗法结束的良好标准下有资格。在敏感性分析中:局部复发百分比GBM增加; DRG25 / 26的成本增加; GTR百分比增加;和胶质胶型使用增加 - 脑径的值改善。此外,在那些活组织检查是唯一的选择的患者中,脑Litt延长了7个月的寿命。由于它以成本提高生存,脑齐特应被视为一种可行的选择,以便以成本提高生存,这似乎对社会具有良好的价值。这种增量成本低于国际和美国的阈值。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号